Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Diaceutics PLC (DIUXF)
Belfast, GB
Diaceutics PLC operates as a global diagnostic commercialization entity, providing pharmaceutical companies worldwide with essential data, sophisticated analytics, and implementation support. Central to its offerings is the DXRX platform, a comprehensive suite designed to address various aspects of precision medicine. This platform delivers: DXRX Data Solutions: Granting access to a vast network of laboratory diagnostic testing data. Key components here include DXRX Signal (for specific data insights), Lab Mapping, a Testing Dashboard, and Physician Mapping services. DXRX Marketplace Solutions: A crucial hub that fosters collaborations between laboratories, pharmaceutical firms, and diagnostic companies to advance precision medicine initiatives. DXRX Patient Journey: Enables pharmaceutical clients to conduct in-depth, longitudinal analyses of individual patient biomarker testing pathways. This insight is vital for pinpointing opportunities for earlier intervention and optimized treatment strategies. DXRX Lab Benchmarking: Empowers laboratories to enhance their competitive standing by comparing critical performance metrics – such as disease profiles, testing methodologies, market share, and turnaround times – against industry peers. DXRX Test Reimbursement: Facilitates pharmaceutical companies' engagement with laboratories to secure funding for the launch of novel companion diagnostics, thereby accelerating test adoption and market penetration. DXRX Test Signal: Provides real-time alerts regarding testing events, enabling pharmaceutical clients to quickly identify patients who may benefit from specific therapies. Beyond the DXRX platform, Diaceutics offers a range of supplementary services. These include strategic consulting for precision medicine diagnostics, as well as diagnostic landscape analysis, planning, implementation, and tracking. The company also provides support for test standardization, quality assessment, report optimization, laboratory technical assistance, test access and reimbursement solutions, comprehensive laboratory training, and educational resources. Established in 2005, Diaceutics PLC maintains its headquarters in Belfast, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.44% | +19.76% | +19.76% | +45.99% | +45.99% | +45.99% | +78.57% | +30.72% | +5.26% | +5.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Diagnostics & Research: +7.9%+19.5% ★ Q4'25: +73.3% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+105.5% ★ Q4'25: +1,051.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+2.0% Q4'25: +2.8% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-0.6% Q4'25: +13.1% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-0.4% Q4'25: +27.2% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.8% Q4'25: +0.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.21× ★ Q4'25: 0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
19.50M
est: 24.19M (-19.4%)
|
23.70M
est: 30.17M (-21.4%)
|
32.16M
est: 32.19M (-0.1%)
|
38.43M
est: 38.43M (+0.0%)
|
46.22M
45.72M – 46.72M
+20.3% YoY
|
55.77M
54.08M – 58.79M
+20.7% YoY
|
66.23M
64.81M – 68.53M
+18.8% YoY
|
76.12M
74.49M – 78.77M
+14.9% YoY
|
| EBITDA |
3.61M
est: 1.96M (+84.0%)
|
2.40M
est: 3.10M (-22.4%)
|
2.77M
est: 4.31M (-35.7%)
|
5.60M
est: 5.15M (+8.8%)
|
6.19M
6.12M – 6.26M
+20.3% YoY
|
7.47M
7.24M – 7.87M
+20.7% YoY
|
8.87M
8.68M – 9.18M
+18.8% YoY
|
10.20M
9.98M – 10.55M
+14.9% YoY
|
| EBIT |
684.0K
est: -794.8K (+186.1%)
|
-2.37M
est: -340.8K (-595.9%)
|
-1.85M
est: -708.5K (-161.7%)
|
-212.0K
est: -845.8K (+74.9%)
|
-1.02M
-1.03M – -1.01M
-20.3% YoY
|
-1.23M
-1.29M – -1.19M
-20.7% YoY
|
-1.46M
-1.51M – -1.43M
-18.8% YoY
|
-1.68M
-1.73M – -1.64M
-14.9% YoY
|
| Net Income |
724.0K
est: 392.2K (+84.6%)
|
-1.75M
est: -1.56M (-12.3%)
|
-1.70M
est: -581.4K (-192.9%)
|
97.0K
est: 93.6K (+3.6%)
|
509.6K
495.3K – 532.6K
+444.3% YoY
|
2.80M
2.72M – 2.93M
+450.0% YoY
|
7.27M
7.06M – 7.59M
+159.3% YoY
|
10.85M
10.55M – 11.34M
+49.3% YoY
|
| SGA |
13.71M
est: 19.12M (-28.3%)
|
22.78M
est: 22.88M (-0.4%)
|
30.74M
est: 25.94M (+18.5%)
|
25.87M
est: 30.97M (-16.4%)
|
37.24M
36.84M – 37.64M
+20.3% YoY
|
44.93M
43.57M – 47.37M
+20.7% YoY
|
53.37M
52.22M – 55.22M
+18.8% YoY
|
61.34M
60.02M – 63.46M
+14.9% YoY
|
| EPS |
0.01
est: 0.00 (+84.7%)
|
-0.02
est: -0.02 (-12.4%)
|
-0.02
est: -0.01 (-195.7%)
|
0.00
est: 0.00 (+9.1%)
|
0.01
0.01 – 0.01
+444.3% YoY
|
0.03
0.03 – 0.03
+450.0% YoY
|
0.09
0.08 – 0.09
+159.3% YoY
|
0.13
0.12 – 0.13
+49.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryan Keeling | Chief Executive Officer & Director | 726.4K | male |
| Nicholas Stewart Roberts | Chief Financial Officer, Secretary & Director | 519.6K | male |
| Peter Keeling | Founder & Executive Chairman | 455.8K | male |
| Jordan Clark | Chief Data Officer? & Executive Director | 336.7K | male |
| Marianna Sciortino | Vice President of Sales | — | — |
| Amie McNiece | Vice President of Marketing | — | — |
| Sandra Blake | Chief People Officer | — | female |
| Ken Ruppel | Vice President of Scientific & Medical Services | — | — |
| Kerri Donaldson | Vice President of Operations | — | — |
| Lauren DeWitt | Executive Vice President of Legal, General Counsel & Group Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DIUXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
